Abbvie androgel case update
AbbVie Claims FDA Never Requested Study of AndroGel Heart Attack Risk
July 20, 2017
In a Chicago courtroom, an executive with drugmaker AbbVie asserted that the company had supplied the U.S. Food and Drug Administration (FDA) with information concerning the links between an elevated heart attack risk and its topical testosterone replacement therapy drug AndroGel, but that the agency never requested a formal study.
Linda Scarazzini, AbbVie’s vice president of global pharmacovigilance and patient safety, stated that the company provided all relevant data to the FDA, and the FDA did not find that the drug was associated with an elevated risk of heart attacks.
At issue in the suit is whether AbbVie promoted the prescription of AndroGel for patients for whom it was not medically necessary, thereby promoting health hazards such as an increased risk of heart attack.
The current case was brought by Jesse Mitchell, who suffered a heart attack in 2012 that he believes was caused by AndroGel. Mitchell’s case is the first to reach trial in a Multi-District Litigation (MDL) case that involves thousands of other suits.
The case is ongoing in Chicago.
If you’ve taken AndroGel and have had a heart attack, you may be entitled to be part of this or another lawsuit. Contact TheLawFirm.com to learn how we can help you stand up for your healthcare rights.
TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including:
Real lawyers, real results!
no recovery, no fee!